9800/3	Leukemia, NOS
		Subacute leukemia, NOS [obs]
		Chronic leukemia, NOS [obs]
		Aleukemic leukemia, NOS [obs]
	9801/3	Acute leukemia, NOS
		TBL1XR1/MECOM fusion::del(3)(q26.2q26.3) TBL1XR1/MECOM
		Mixed phenotype acute leukemia (MPAL)
		-20 or monosomy 20
		+X solely in myeloid malignancies
		der(2)t(1;2)(q12-21;q37)
		der(4)t(1;4)(q11-32;q34-35)
		Blast cell leukemia
		Stem cell leukemia
		Undifferentiated leukaemia
	9805/3	Acute biphenotypic leukemia
		Biphenotypic Acute Leukaemia (BAL)
		i(5)(p10) in hematological malignancies
		-20 or monosomy 20
		Acute mixed lineage leukemia
		Acute bilineal leukemia
	9806/3	Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1
		Mixed phenotype acute leukemia (MPAL)
		t(9;22)(q34;q11) BCR/ABL1 in ALL
	9807/3	Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged
		del(11)(q23q23) KMT2A/CBL::t(11;11)(q23;q23) KMT2A/CBL
		del(11)(q23q23) KMT2A/ARHGEF12
		ins(5;11)(q31;q13q23) KMT2A/AFF4
		Mixed phenotype acute leukemia (MPAL)
		t(1;11)(p32;q23) KMT2A/EPS15
		t(2;11)(p21;q23) KMT2A/?
		t(2;11)(q11;q23) KMT2A/AFF3
		t(2;11)(q37;q23) KMT2A/SEPT2
		t(3;11)(p21;q23) KMT2A/NCKIPSD
		t(3;11)(q21;q23) KMT2A/EEFSEC
		t(3;11)(q28;q23) KMT2A/LPP
		t(4;11)(q21;q23) KMT2A/AFF1
		t(4;11)(q35;q23) KMT2A/SORBS2
		t(5;11)(q31;q23) KMT2A/ARHGAP26
		t(6;11)(q27;q23) KMT2A/AFDN
		t(6;11)(q13;q23) KMT2A/SMAP1
		t(6;11)(q15;q23) KMT2A/?
		t(9;11)(q34;q23) FNBP1/KMT2A
		t(9;11)(q34;q23) KMT2A/DAB2IP
		t(X;11)(q13;q23) KMT2A/FOXO4
		t(X;11)(q22;q23) KMT2A/?
		t(X;11)(q24;q23) KMT2A/SEPT6
		t(10;11)(p12;q23) KMT2A/MLLT10
		t(10;11)(p11.2;q23) KMT2A/ABI1
		t(10;11)(q22;q23) KMT2A/TET1
		t(11;11)(q13;q23) KMT2A/ARHGEF17
		t(11;11)(q14;q23) KMT2A/PICALM::inv(11)(q14q23) KMT2A/PICALM
		t(11;14)(q23;q32) KMT2A/CEP170B
		t(11;15)(q23;q14) KMT2A/CASC5
		t(11;15)(q23;q14) KMT2A/ZFYVE19
		t(11;16)(q23;p13.3) KMT2A/CREBBP
		t(11;17)(q23;q25) KMT2A/SEPT9
		t(11;17)(q23;p13) KMT2A/GAS7
		t(11;17)(q23;q12) KMT2A/RARA
		t(11;17)(q23;q12-21) KMT2A/MLLT6
		t(11;17)(q23;q12-21) KMT2A/LASP1
		t(11;19)(q23;p13.1) KMT2A/ELL
		t(11;19)(q23;p13.3) KMT2A/MLLT1
		t(11;19)(q23;p13) KMT2A/SH3GL1
		t(1;11)(q21;q23) KMT2A/MLLT11
		t(11;20)(q23;q11) KMT2A/MAPRE1
		t(11;22)(q23;q11.2) KMT2A/SEPT5
		t(11;22)(q23;q13) KMT2A/EP300
		11q23 rearrangements (KMT2A) in childhood acute lymphoblastic leukemia
		11q23 rearrangements (KMT2A) in de novo childhood acute myeloid leukemia
		11q23 rearrangements (KMT2A) in leukaemia
		11q23 rearrangements (KMT2A) in therapy related leukaemias
	9808/3	Mixed phenotype acute leukemia, B/myeloid, NOS
		der(5)t(1;5)(q12-q25;q13-q35)
		dic(7;12)(p10-p12;p11-p13)
		i(8)(q10) in ALL
		Mixed phenotype acute leukemia (MPAL)
		+X solely in myeloid malignancies
		t(7;14)(p15;q32)
		t(14;19)(q32;q13) IGH/Various Partners
	9809/3	Mixed phenotype acute leukemia, T/myeloid, NOS
		Mixed phenotype acute leukemia (MPAL)